Montelukast Eg

Montelukast, the active ingredient in Montelukast Eg, is a leukotriene receptor antagonist presented as an oral dosage form for systemic use. It is employed to manage asthma and allergic rhinitis, reducing inflammation and bronchoconstriction in patients of various ages. The medication works by blocking specific inflammatory mediators, helping to improve breathing and reduce nasal symptoms.

GNH USA supplies Montelukast Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable delivery and adherence to regulatory standards across multiple regions.

Montelukast acts on leukotriene pathways to control respiratory and allergic conditions.

Asthma: improves control of persistent asthma and reduces the frequency of exacerbations. Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal or perennial allergic rhinitis. Exercise‑induced bronchoconstriction: prevents narrowing of the airways triggered by physical activity.

Montelukast may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea

Serious or Rare Side Effects: - Allergic reactions such as rash, angioedema or anaphylaxis - Mood changes including depression, anxiety or suicidal thoughts - Stevens‑Johnson syndrome or toxic epidermal necrolysis

Before initiating therapy, clinicians should consider several safety aspects.

Assess asthma control: verify that baseline disease management is optimized. Monitor for neuropsychiatric symptoms: watch for mood changes or suicidal ideation during treatment. Use with caution in hepatic impairment: dose adjustment may be required. Avoid in individuals with known hypersensitivity to montelukast or tablet excipients. Review concomitant medications: assess for potential drug‑drug interactions. Store at below 25°C: keep in the original pack, protect from moisture.

Montelukast can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) may increase montelukast plasma concentrations. - Rifampin or other potent CYP inducers may reduce therapeutic effectiveness.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs) may augment neuropsychiatric adverse effects. - Beta‑agonist bronchodilators may have additive bronchodilatory effect. - Warfarin may require INR monitoring due to possible alteration in plasma protein binding.